Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab

• Published in: Frontiers in immunology Vol. 14; p. 1188523
• Main Authors: Chen, Peng-Yu, Li, Zi-Yun, Cai, Sui-Qing
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 03.08.2023
• Subjects: Adalimumab; Adalimumab - therapeutic use; Antibodies, Bispecific - adverse effects; Antibodies, Bispecific - therapeutic use; Cadonilimab/AK104; Carcinoma, Hepatocellular - drug therapy; case report; Humans; immune checkpoint inhibitor; Immune Checkpoint Inhibitors - adverse effects; Immune Checkpoint Inhibitors - therapeutic use; immune-related adverse events; Immunology; Liver Neoplasms - drug therapy; Male; Middle Aged; Stevens-Johnson Syndrome - drug therapy; Stevens-Johnson Syndrome - etiology; toxic epidermal necrolysis; Treatment Outcome; Withholding Treatment; Cadonilimab/AK104; case report; immune checkpoint inhibitor; Adalimumab; immune-related adverse events; toxic epidermal necrolysis

Cadonilimab is the first bi-specific antibody approved for certain malignancies in June 2022, which has a modified Fc structure to reduce immune-related adverse events. To date, no reports have described Cadonilimab-related toxic epidermal necrolysis (TEN). Here, we report the first case of TEN-like...